Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial

Diabetologia

Volumn 56, Issue 12, 2013, Pages 2582-2592

  Lavalle Gonzalez F J ^a   Januszewicz, A ^b   Davidson, J ^c   Tong, C ^d   Qiu, R ^d   Canovatchel, W ^d   Meininger, G ^d  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b INSTITUTE OF CARDIOLOGY   (Poland)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Canagliflozin; Metformin; Sitagliptin; Sodium glucose co transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SITAGLIPTIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNGAL GENITAL INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; POLYURIA; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ADOLESCENT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; THIOPHENES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84887997289     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-3039-1     Document Type: Article

References (20)

1. American Diabetes Association (2012) Standards of medical care in diabetes - 2012. Diabetes Care 35:S11-S63
2. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577-1596, Erratum in 56:680
3. National Institute for Health and Clinical Excellence (2009) Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87. NICE, London
4. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344:e1369
5. Rosenstock J, Aggarwal N, Polidori D et al (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35:1232-1238
6. Stenlof K, Cefalu WT, Kim K-A et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372-382
7. Yale JF, Bakris G, Cariou B et al (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463-473
8. Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 36:2508-2515
9. Cefalu WT, Leiter LA, Yoon K-H et al (2013) Canagliflozin promotes body weight loss compared with glimepiride while providing glycaemic efficacy in subjects with type 2 diabetes on background metformin: 52-week findings from a randomised, double-blind trial. Lancet. doi: 10.1016/S0140-6736(13)60683-2
10. Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K (2013) Efficacy and safety of canagliflozin in older subjects with type 2 diabetes: a randomized trial. Hosp Pract 41:72-84
11. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223-2233
12. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11:43
13. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33:2217-2224
14. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ (2013) A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15:721-728
15. Food and Drug Administration (2008) Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. FDA, Rockville, MD
16. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) (2012) Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. CPMP/EWP/1080/00 Rev. 1. EMA, London
17. Weidmann P, de Courten M, Ferrari P (1992) Effect of diuretics on the plasma lipid profile. Eur Heart J 13(Suppl G):61-67
18. Nicolle LE, Capuano G, Fung A, Usiskin K (2013) Urinary tract infection (UTI) with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM). Diabetes 62:A296 (Abstract)
19. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9:194-205
20. Nauck MA, del Prato S, Meier JJ et al (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34:2015-2022